In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
Session

Congress : ESC Congress 2018

Topic : Diabetes and the Heart

  • Session type : Satellite Symposium
  • Date : 25 August 2018
  • Time : 15:30 - 17:00
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

6 presentations in this session

Welcome and introduction - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Evidence-based approaches to reducing premature cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease.

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : D Mcguire (Dallas,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Applying evidence in practice: appropriate use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in the cardiology clinic.

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : JA Udell (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE), D Mcguire (Dallas,US), JA Udell (Toronto,CA), S Verma (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Exploring the effects of SGLT2 inhibition in ongoing trials.

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : S Verma (Toronto,CA)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Summary and close - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are